Nothing said here yet.
to join the conversation.
| Jonsson PatrikEVP & President, LLY Int'l | Sell | 6,500 | $7.6M | Mon, Aug 17 |
| John Boozman | Sell | $8.0K | Fri, Nov 21 | Mon, Aug 24 |
| Thomas H Tuberville | Sell | $32.5K | Tue, Apr 15 | Wed, Aug 5 |
| Alan Armstrong | Sell | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| Dan Newhouse | Sell | $8.0K | Fri, Jul 10 | Fri, Jul 10 |
| Gilbert Cisneros | Buy | $75.0K | Wed, Jun 10 | Thu, Jul 2 |
| Michael Rulli | Sell | $8.0K | Wed, Jul 1 | Wed, Jul 1 |
| Gilbert Cisneros | Buy | $8.0K | Tue, Apr 14 | Thu, May 7 |
| Byron Donalds | Buy | $8.0K | Thu, Apr 2 | Fri, May 1 |
| Elizabeth Fletcher | Sell | $8.0K | Wed, Apr 8 | Mon, Apr 13 |
| Michael Rulli | Buy | $8.0K | Fri, Jan 2 | Fri, Jan 2 |
| Michael Rulli | Sell | $8.0K | Tue, Dec 2 | Tue, Dec 2 |
Lilly shares hit a record as weight-loss drugs became more accessible.
Eli Lilly stock is trading at a record high.
GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.
Key TakeawaysEli Lilly’s Q3 revenue rose 39% to $24. 4 billion, and Mounjaro and Zepbound brought in about $16.
Key TakeawaysEli Lilly shares rose 11% in the week through Oct. 30 to a record close after a third-quarter beat and a $5.
Eli Lilly and Company (NYSE:LLY) raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound incretin medicines and continued growth across international…
LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook.
Eli Lilly's business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate.
Mounjaro and Zepbound built Lilly into a trillion-dollar company, but a surge in oncology, immunology, and neuroscience revenue hints that the real growth story is just getting started.
As tokenized stock trading continues to gain traction, so too does the list of companies that object to it. In the video above, Scott Melker outlines key details of the objections from Walmart (WMT), Eli Lilly (LLY), and others.
Eli Lilly and Co (NYSE:LLY) is benefiting from exceptional global demand for its obesity and diabetes medicines, with strong sales volumes offsetting falling prices and supporting further earnings growth, according to UBS, which sees the company’s growth…
Key Stats for Eli Lilly StockCurrent Price: $1,373. 70Target Price (Mid): ~$2,340Street Target: ~$1,337Potential Total Return: ~70%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly (LLY:NYSE) closed at a record $1,373.